The Latest Breaking News from Medicare

Legislation to limit insulin costs for people with diabetes is getting a new push in the Senate

UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ:KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022.  Eysuvis now has coverage for approximately 118 million lives or 70% of all commercial lives. Kala also announced that Cigna Medicare had added Eysuvis as a preferred brand effective…

Health Minister Greg Hunt says the government remains committed to Medicare with almost nine out 10 GP visits provided with no out-of-pocket cost.

As few as 30% of patients being properly bulk-billed despite health minister claiming it is nearly 90%, report says

As a parting gesture to a pandemic-ravaged city, former New York Mayor Bill de Blasio hoped to provide the city with a gift that would keep on giving: new health insurance for 250,000 city retirees partly funded by the federal government. Although he promised better benefits and no change in…

The Medicare rebate for getting an intra-uterine device (IUD) inserted has been raised but doctors say it still does not come close to covering the cost of the procedure.

Cognitive behavioural therapy (CBT) is one of the most popular forms of talking therapy. It is the treatment of choice for depression and anxiety and is a staple of public healthcare systems, such as the NHS and the Australian Medicare system. CBT’s understanding of mental illness and therapeutic techniques is…

A congressional effort to fix the nation’s deteriorating mail service may come at the expense of an even bigger and more complicated problem: Medicare solvency.

Royal Australian College of General Practitioners calls for Medicare restructure amid psychiatrist shortage and gaps in regional coverage

A roundup of the latest of interest to financial advisers includes research on the Great American Retirement Fraud, fearless forecasts, and the problem with Roth conversions in 2022.

The prices are still relentlessly high.